antiinfect
antibodi
new
opportun
proven
technolog
late
behr
kitasato
develop
first
wide
avail
effect
antimicrobi
treatment
show
transfer
immun
sera
could
provid
passiv
immun
diphtheria
next
year
serum
transfer
use
success
treatment
mani
infect
includ
pneumococc
pneumonia
meningococc
mening
streptococc
infect
howev
due
safeti
concern
discoveri
antibiot
serum
therapi
larg
abandon
late
except
limit
number
toxinand
viralmedi
diseas
continu
reli
serum
due
lack
altern
option
mainstream
human
immunoglobulin
prepar
use
today
recogniz
old
serum
therapi
product
highli
purifi
treat
filter
ensur
viral
inactiv
remov
use
highli
reproduc
releas
assay
avoid
histor
problem
associ
polyclon
antibodi
ab
impur
resid
virus
lot
variat
two
troubl
develop
infecti
diseas
led
necessari
resurg
develop
antibodybas
therapeut
first
rampant
emerg
multidrug
resist
form
new
old
pathogen
second
recent
explos
world
immunocompromis
popul
provid
unprotect
popul
combin
complex
infect
emerg
new
adjunct
antibodi
therapeut
everi
major
diseas
infect
type
may
best
strategi
treat
prevent
new
wave
drug
resist
infecti
diseas
pathogenesi
infecti
organ
complex
coevolut
host
pathogen
evolutionari
time
result
mani
type
inflammatori
respons
fine
balanc
exist
protect
versu
zealou
host
respons
either
deregul
subvers
pathogen
although
ab
therapi
either
develop
use
mani
viral
bacteri
fungal
prionmedi
infect
tabl
pathogen
exhibit
huge
differ
patholog
virul
gener
highli
virul
acut
infect
like
requir
immedi
protect
provid
antibodi
treatment
moreov
outbreak
situat
earli
implement
public
health
measur
may
help
limit
spread
vaccin
avail
shown
sar
stretch
dramat
increas
risk
exposur
immunotherapi
may
provid
mean
protect
prefer
convent
vaccin
halflif
passiv
antibodi
therapeut
obviat
use
type
product
except
need
infect
suitabl
antibodi
therapi
develop
therapeut
cost
hundr
million
dollar
take
year
find
way
variou
stage
research
develop
clinic
develop
govern
regulatori
approv
process
end
process
manufactur
cost
factor
cost
per
dose
final
product
tabl
cheaper
manufactur
antibiot
advantag
post
develop
fda
approv
process
antibodi
product
produc
via
novel
recombin
express
system
gain
regulatori
approv
monoclon
antibodi
mab
manufactur
remain
limit
cell
cultur
current
everi
fda
approv
mab
manufactur
use
classic
mammalian
cell
cultur
express
system
consid
viabl
develop
antibodi
therapi
infecti
diseas
pathogen
need
specif
attribut
antibodi
must
show
efficaci
vivo
help
clear
infect
reduc
infecti
burden
reduc
time
heal
prevent
infectionintox
occur
howev
address
biolog
antibodi
numer
issu
around
target
market
drive
commerci
interest
continu
develop
antibodi
therapeut
due
inher
narrow
specif
high
cost
product
larg
depend
compet
antimicrobi
therapi
vaccin
exampl
despit
signific
invest
develop
protect
mab
clostridium
difficil
toxin
sever
clinic
trial
novel
toxoid
vaccin
sanofi
pasteur
may
convert
rel
larg
grow
market
c
difficil
treatment
nich
market
breakthrough
infect
unimmun
immunocompromis
contrast
advent
c
difficil
specif
antibiot
fidaxomicin
develop
optim
pharmaceut
purportedli
leav
normal
gut
flora
intact
clear
c
difficil
would
probabl
leav
antitoxin
therapeut
market
intact
immunotherapeut
could
still
administ
adjunct
therapi
specif
remov
effect
toxin
summari
characterist
determin
pro
con
variou
class
compet
antimicrobi
drug
shown
tabl
monoclon
antibodi
uniqu
class
drug
numer
biolog
effect
depend
upon
isotyp
induc
bind
singl
microbi
epitop
fig
mani
good
review
exist
discuss
contemporari
mab
develop
specif
infecti
agent
mani
effect
depend
compon
immun
system
includ
antibodi
depend
cellular
cytotox
adcc
complement
depend
cytotox
cdc
opson
immunomodul
viru
neutral
achiev
interf
one
variou
method
use
virus
enter
host
cell
case
human
immunodefici
viru
hiv
ab
prevent
viral
attach
host
cell
bind
either
envelop
protein
viru
host
receptor
antibodi
may
also
neutral
influenza
viru
prevent
low
ph
induc
conform
chang
requir
hemagglutinin
prevent
releas
progeni
virion
infect
cell
interestingli
antibodi
also
directli
antimicrobi
describ
candida
albican
cryptococcu
neoforman
latter
igm
mab
induc
fungal
gene
express
metabol
chang
anim
model
cryptococcu
antiinfect
antibodi
monoclon
polyclon
immunoglobulin
high
titer
plasma
immun
individu
poli
ig
bulk
intraven
immun
globulin
ivig
remain
predomin
therapeut
use
today
passiv
antibodi
therapi
treat
infecti
diseas
unlik
modest
antigen
differ
normal
tumor
cell
warrant
monospecif
approach
treat
cancer
infecti
agent
gener
foreign
immun
system
allow
less
specif
readili
avail
polyclon
approach
becom
norm
treat
infecti
diseas
ivig
treatment
diseas
review
recent
recommend
treatment
kawasaki
diseas
cytomegaloviru
cmv
induc
pneumon
neonat
sepsi
rotavir
enterocol
staphylococc
toxic
shock
syndrom
high
titer
altern
poli
ig
use
clinic
prevent
infect
caus
cmv
hepat
b
virus
hbv
rabi
varicella
measl
viru
antitetanu
ig
use
treat
tetanu
rabi
hepat
b
tetanu
donor
usual
vaccin
cmv
measl
varicella
typic
screen
high
titer
regard
stimul
human
donor
vaccin
use
develop
effect
polyclon
anthrax
immun
globulin
aig
passiv
therapi
poli
ig
also
use
prevent
mothertochild
transmiss
hbv
varicellazost
viru
convers
singl
mab
rsv
current
licens
prophylact
treatment
infecti
diseas
polyclon
monoclon
igg
prepar
success
use
infecti
diseas
prevent
major
experi
purifi
polyclon
igg
advanc
mab
technolog
necessit
movement
toward
defin
expens
manufactur
mabbas
therapi
abil
reproduc
mab
therapeut
scalabl
quantiti
meet
demand
repres
signific
differ
harvest
process
poli
ig
prepar
furthermor
although
human
igg
prepar
use
today
highest
safeti
record
biolog
clear
pathway
fda
still
linger
fear
regard
chanc
human
poli
ig
transmit
infect
even
exceedingli
low
exampl
uk
citizen
still
allow
donat
blood
usa
uk
fall
prion
incid
earli
despit
fact
resin
complex
agent
remov
prion
well
entrench
poli
igg
purif
protocol
plasma
suppli
although
concern
could
reduc
use
mab
produc
via
tissu
cultur
microbi
express
system
cost
per
dose
mab
significantli
higher
may
warrant
develop
mani
nich
market
product
tabl
inde
alway
obviou
model
relev
qualifi
treatment
antigen
go
protect
mani
case
poli
ig
proce
cheaper
altern
mab
case
vaccin
least
phase
avail
harvest
poli
ig
endem
region
may
allevi
concern
low
titer
ivig
reagent
instanc
ivig
titer
west
nile
viru
collect
select
isra
donor
treat
infect
furthermor
mab
typic
limit
specif
function
fragil
macromolecul
expens
produc
take
consider
longer
isol
optim
poli
ig
ivig
current
statu
research
aim
expand
limit
mab
term
specif
function
particular
deal
infecti
agent
discuss
inher
use
singl
design
antibodi
protect
target
chosen
isotyp
effector
function
mediat
singl
isotyp
must
alon
combat
infect
polyclon
igg
prepar
rel
resist
antigen
variat
target
rang
epitop
also
widen
biolog
effector
function
consist
multipl
class
antibodi
compris
typic
abil
induc
adcc
cdc
depend
isotyp
glycosyl
statu
antibodi
thu
variabl
inher
polyclon
prepar
mani
case
provid
ad
benefit
protect
advantag
isotyp
characterist
make
less
desir
immun
respons
mani
new
recombin
fc
scaffold
design
recent
year
among
igg
isotyp
long
isotyp
choic
mab
cancer
therapi
due
long
half
life
partial
protein
antigen
abil
activ
complement
affin
fc
receptor
fcgi
ii
iiiab
synagi
mab
prevent
sever
rsv
infant
remain
sole
mab
infecti
agent
market
use
human
mab
isotyp
approv
infecti
diseas
date
howev
although
effect
induc
adcc
natur
killer
nk
cell
consider
less
potent
activ
polymorphonuclear
cell
pmn
furthermor
activ
inflammatori
pathway
detriment
depend
immun
statu
individu
class
rel
inert
effector
function
howev
gener
respons
stimul
inher
inflammatori
bacteri
cell
wall
polysaccharid
make
import
protect
bacteri
infect
moreov
two
format
mab
approv
use
human
chronic
diseas
least
eight
current
clinic
develop
owe
longest
halflif
fewest
allotyp
inabl
activ
complement
class
similar
biolog
function
receiv
littl
use
date
recombin
mab
due
consider
shorter
halflif
extens
polymorph
class
uniqu
inabl
crosslink
antigen
vitro
gener
respons
persist
antigen
stimul
make
import
chronic
viral
bacteri
infect
least
two
class
mab
market
least
anoth
nine
differ
phase
research
develop
chronic
diseas
indic
natur
infect
igm
class
antibodi
gener
produc
earliest
respons
tdepend
antigen
persist
respons
tcellindepend
antigen
lipopolysaccharid
lp
pentamer
form
igm
make
highli
avid
although
atyp
commerci
purifi
potent
induc
cdc
human
igm
mab
kenta
biotech
develop
time
target
murin
mab
protein
r
mab
show
protect
vivo
via
reduct
fungal
burden
less
inflamm
murin
model
protect
antigen
cryptococcu
neoforman
murin
mab
anti
bglucan
r
mab
caus
reduct
fungal
burden
brain
liver
mice
system
infect
highli
virul
encapsul
c
neoforman
strain
cryptococcu
neoforman
murin
mab
anticapsular
ps
r
switch
variant
prolong
surviv
lethal
infect
mice
wherea
mab
protect
c
defici
mice
murin
mab
anticel
wall
surfac
hypha
r
murin
model
invas
aspergillosi
candida
spp
efungumab
mycograb
humab
hsp
c
novarti
prevent
conform
chang
need
fungal
viabil
show
efficaci
human
lower
mortal
abandon
pneumocysti
carnii
murin
mab
f
ab
deriv
r
reduc
infecti
burden
intranas
immunoprophylaxi
model
market
r
research
c
commerci
develop
provid
express
nativ
pentam
achiev
commerci
scale
describ
recent
human
cell
polymer
igm
may
prove
isotyp
choic
treatment
mani
bacteria
particularli
local
infect
mucos
surfac
human
uniqu
olink
glycoform
rel
short
halflif
may
also
best
suit
use
local
inde
intranas
administr
iga
mab
preor
postinfect
protect
mice
subleth
challeng
influenza
viru
even
igd
bind
respiratori
gramneg
bacteria
moraxella
catarrhali
haemophilu
influenza
mediat
intern
mast
cell
basophil
trigger
innat
antimicrobi
respons
clearli
choic
mab
isotyp
crucial
decis
ultim
determin
function
vivo
factor
dose
rout
administr
halflif
site
infect
also
requir
attent
choic
isotyp
howev
often
crystal
clear
illustr
recent
observ
despit
potent
cdc
adcc
induc
abil
c
neoforman
mous
model
human
abl
protect
mice
infect
antibodi
carri
variabl
region
differ
constant
region
passiv
administ
also
passiv
administ
serum
igg
shown
protect
pigtail
macaqu
rotaviru
infect
mucos
gut
model
find
point
still
empir
natur
design
therapeut
antibodi
treat
infecti
diseas
inher
flexibl
recombin
mab
approach
permit
modif
immunoglobulin
fit
specif
need
address
problem
pose
use
singl
isotyp
possibl
engin
fc
region
increas
biolog
function
target
amino
acid
substitut
increas
affin
fc
region
fcgriiia
increas
adcc
natur
killer
cell
fold
glycosyl
pattern
fc
region
alter
increas
adcc
differ
approach
engin
bispecif
mab
one
half
fab
bind
antibodi
effector
mechan
use
combat
microorgan
mediat
variou
isotyp
human
immunoglobulin
microb
recogn
host
receptor
exampl
includ
mab
specif
either
p
aeruginosa
bacteriophag
also
bind
host
complement
receptor
fab
domain
group
taken
lesson
learn
clinic
trial
involv
immunotoxin
base
therapi
oncolog
appli
success
infecti
diseas
mab
conjug
radioisotop
use
treat
experiment
infect
c
neoforman
histoplasma
capsulatum
streptococcu
pneumonia
hiv
monoclon
specif
pro
con
exquisit
specif
mab
may
biggest
advantag
biggest
disadvantag
high
specif
mab
therapi
result
littl
cross
reactiv
host
cell
normal
flora
import
consid
link
chronic
diseas
certain
type
cancer
use
broad
spectrum
antibiot
tabl
furthermor
mab
therapi
unlik
select
drug
resist
extran
microb
due
lack
intramicrob
cross
reactiv
unlik
poli
igg
carri
mani
irrelev
specif
mab
develop
target
specif
microbi
epitop
import
pathogenesi
therebi
theoret
increas
potenc
specif
biolog
activ
per
dose
particular
target
epitop
highli
protect
polyclon
also
isoagglutinin
anti
anti
b
undesir
case
nevertheless
high
specif
also
impli
narrowspectrum
antimicrobi
drug
quick
accur
diagnosi
requir
therapi
result
small
market
antiinfect
mab
may
limit
econom
feasibl
mab
base
approach
certain
instanc
overshadow
breadth
reactiv
poli
igg
come
target
multipl
epitop
multipl
igg
isotyp
mani
cut
edg
strategi
develop
address
narrow
specif
mab
therapi
broaden
util
pathogen
rang
summar
fig
typic
select
ab
protect
antigen
key
criterion
develop
effect
passiv
immun
strategi
highli
conserv
antigen
valuabl
target
passiv
immunotherapeut
reduc
number
mab
need
make
effect
cocktail
chanc
escap
antibodi
gener
place
sever
key
theme
certain
type
infect
consist
involv
predict
cadr
infecti
agent
may
associ
particular
injuri
eg
post
burn
infect
environment
exposur
eg
contamin
food
intent
biothreat
releas
eg
hemorrhag
virus
chemic
program
mab
unlimit
chemic
divers
synthet
molecul
coupl
effector
function
antibodi
provid
mean
singl
mab
may
specif
multipl
epitop
fashion
effector
function
brought
preimmun
circul
antibodi
tag
small
molecul
adapt
small
molecul
singl
chain
variabl
fragment
scfv
adapt
express
cheapli
escherichia
coli
significantli
less
expens
manufactur
fulllength
mab
target
virul
factor
associ
antigensepitop
current
trend
bacteri
immunotherapeut
target
virul
associ
factor
promis
candid
sever
reason
first
prevent
direct
damag
host
caus
larg
bacteri
exotoxin
lp
cytolysi
inflamm
second
virul
factor
lend
resist
harsh
immunolog
condit
seen
capsul
spore
antigen
variat
third
virul
factor
allow
adhes
entri
host
cell
environ
lead
evas
chronic
infect
target
singl
virul
factor
effect
diseas
symptom
pathogenesi
interrupt
exampl
gastrointestin
tract
infect
c
difficil
two
larg
cytotoxin
tcda
tcd
b
caus
associ
diseas
diarrhea
recent
merck
publish
clinic
data
show
cocktail
two
mab
one
tcda
anoth
tcdb
mgkg
greatli
reduc
reoccurr
rate
compar
control
probabl
due
reduc
damag
intestin
line
concept
target
virul
factor
confound
case
bacterium
express
plethora
virul
factor
collect
contribut
diseas
exampl
staphylococcu
aurea
produc
broad
rang
virul
factor
toxin
may
tempor
role
specif
type
infect
approach
target
antigen
variabl
capsul
clump
factor
clfa
alpha
hemolysin
final
pantonvalentin
leukocidin
pvl
case
remov
one
virul
factor
seem
compens
anoth
occur
target
surfac
structur
housekeep
protein
lsaa
discuss
may
appropri
relat
strategi
target
bacteri
protein
indirect
role
pathogenesi
henc
subject
less
select
pressur
antigen
variat
broadli
protect
antibodi
common
treatment
mani
bacteria
includ
one
disconcert
modern
infect
methicillinresist
aureu
mrsa
recent
dr
gerald
pier
alopexx
develop
human
mab
carbohydr
backbon
poli
nacetylglucosamin
pnag
aureu
mab
effect
initi
model
mrsa
induc
opson
cdc
mab
promis
immunotherapi
prophylaxi
adjunct
treatment
mrsa
relat
studi
mab
target
housekeep
protein
lsaa
suggest
lytic
transglycosylas
aureu
provid
protect
mous
model
promot
opson
induc
highli
reactiv
oxygen
speci
mab
quorum
sens
autoinduc
protect
mice
lethal
challeng
aureu
albeit
use
clinic
irrelev
dosag
mab
specif
type
iii
secret
system
compon
gramneg
bacteria
yersinia
speci
p
aeruginosa
aeromona
salmonicida
shown
protect
anim
model
well
mab
also
use
multidrug
efflux
pump
c
difficil
enterococcu
speci
part
combin
therapi
small
molecul
pump
inhibitor
fungal
infect
may
promis
area
mab
therapi
due
presenc
conserv
epitop
speci
therapi
mab
specif
laminarin
betaglucan
effect
induc
fungal
phagocytosi
monocyt
prevent
infect
c
neoforman
c
albican
aspergilli
spp
incred
variabl
virus
pose
signific
challeng
mab
therapi
one
way
counter
use
recombin
technolog
deriv
antibodi
specif
epitop
conserv
among
differ
viral
strain
use
phage
display
sui
et
al
select
specif
mab
capabl
neutral
similar
approach
use
select
cross
protect
mab
sar
coronaviru
dengu
viru
type
although
potenti
advantag
outbreak
condit
diagnos
delay
treatment
virus
capabl
great
antigen
variat
use
singl
mab
ideal
reason
discuss
altern
target
viral
proteom
sever
mab
develop
target
host
protein
doubl
viru
receptor
coreceptor
mab
inhibit
entri
divers
rang
viru
subtyp
includ
new
world
arenavirus
antitransferrin
receptor
mab
hcv
mab
sever
r
tropic
virus
mab
show
potenti
mab
host
protein
long
way
clinic
use
larg
due
complic
inher
block
host
receptor
exampl
block
receptor
may
impair
host
abil
fight
viral
infect
west
nile
viru
involv
lymphocyt
traffic
brain
lastli
one
particularli
promis
area
research
use
antiphospholipid
mab
capabl
identifi
viral
infect
cell
induc
adcc
mab
design
bavituximab
peregrin
pharmaceut
function
recogn
phosphatidylserin
normal
inaccess
serum
antibodi
upon
virusinduc
cell
activ
phosphatidylserin
expos
cell
surfac
due
loss
lipid
symmetri
allow
mab
bind
mab
prevent
cmv
pichind
arenaviru
infect
mice
clinic
trial
current
underway
treatment
hcv
hiv
potent
neutral
abil
mab
inadvert
result
increas
antigen
escap
experiment
infect
highli
variant
rna
virus
inde
treatment
singl
mab
culmin
escap
variant
treatment
hiv
hepat
c
viru
hcv
influenza
coun
exploit
recombin
technolog
address
monospecif
issu
surround
mab
therapi
treatmentprevent
infecti
diseas
ter
scientist
devis
mixtur
two
mab
specif
distinct
protect
epitop
greatli
prevent
rise
escap
mutant
model
infect
inde
develop
cocktail
explor
influenza
sar
coronaviru
lymphocyt
choriomening
viru
hcv
hbv
rabi
viru
call
cocktail
mab
address
two
major
problem
pose
target
singl
epitop
first
target
minimum
two
neutral
epitop
escap
mutant
gener
mab
clear
complement
antibodi
second
increas
antibodi
densiti
valenc
viral
surfac
may
import
factor
viru
neutral
neutral
abil
antibodi
amplifi
consider
promis
recent
develop
concern
antibodi
hepat
c
viru
hcv
lead
caus
liver
diseas
lead
transplant
usa
antigen
variat
hcv
remain
seriou
challeng
antibodi
therapi
activ
vaccin
design
poli
ig
hcv
one
mean
might
dealt
antibodi
would
prepar
immun
distinct
hcv
viru
vaccin
date
activ
vaccin
avail
hcv
possibl
rout
therapeut
law
et
al
instead
identifi
human
mab
neutral
genet
divers
hcv
isol
use
phage
display
mab
isol
use
recombin
hcv
glycoprotein
fab
phage
librari
develop
bone
marrow
rna
donor
chronic
infect
hcv
mab
elegantli
shown
bind
discontinu
epitop
cluster
three
distinct
antigen
region
protein
one
antigen
region
appear
highli
conserv
among
hcv
genotyp
furthermor
mab
show
protect
heterolog
hcv
quasispeci
challeng
human
liverchimer
mous
model
repres
major
advanc
lack
suitabl
model
year
prevent
advanc
field
result
provid
strong
evid
broadli
neutral
antibodi
hcv
protect
heterolog
hcv
viru
infect
furthermor
suggest
prophylact
vaccin
hcv
may
achiev
may
avoid
potenti
antibodi
enhanc
infect
effect
may
due
irrelev
antibodi
poli
igg
prepar
advent
approv
phase
vaccin
would
lead
rapidli
potenti
donor
stimul
program
develop
human
polyclon
therapeut
test
immunotherapi
also
one
promis
approach
treatment
prion
diseas
white
et
al
first
show
mab
could
inhibit
prion
replic
delay
diseas
develop
recent
camelid
antibodi
specif
prp
c
prp
sc
demonstr
abil
cross
blood
brain
barrier
reduc
prion
replic
vivo
elimin
prion
replic
neuroblastoma
cell
vitro
becom
evid
treatment
infecti
diseas
multipl
mab
probabl
requir
provid
optim
protect
mab
cocktail
develop
address
problem
anoth
approach
may
coupl
antibodi
therapi
exist
antimicrobi
protocol
clinic
develop
new
antibodi
therapi
infecti
diseas
requir
clinician
includ
current
standard
care
mani
case
antibiot
antivir
antibodi
act
synergi
antibiot
antivir
provid
increas
protect
infect
tabl
inde
natur
resist
bacteria
render
suscept
antibiot
mab
therapi
antivir
increas
efficaci
antivir
mab
inhibit
viral
replic
therebi
decreas
likelihood
escap
mutant
nich
market
prevail
antibodi
therapi
infecti
diseas
diseas
pathogen
larg
potenti
market
gener
approach
vaccin
antibiot
standpoint
develop
immunotherapi
prevent
sever
rsv
infect
young
children
exemplifi
complex
develop
treatment
infecti
diseas
tend
specif
target
popul
origin
poli
ig
product
respigam
develop
medimmun
approv
prophylact
use
infant
efficaci
human
mab
product
call
synagi
palivizumab
design
replac
respigam
synagi
remain
mab
approv
infecti
diseas
human
cost
effect
rel
respigam
still
analysi
howev
defin
product
produc
tissu
cultur
infinit
despit
focus
effort
medimmuneastrazeneca
gain
regulatori
approv
third
gener
fulli
human
mab
treatment
numax
motavizumab
higher
affin
fulli
human
replac
synagi
long
underway
howev
astrazeneca
recent
announc
discontinu
develop
numax
despit
million
dollar
invest
due
unforeseen
complic
aros
clinic
test
regulatori
approv
process
thu
nich
market
requir
differ
approach
biotechnolog
invest
time
expens
research
opportun
cost
nich
market
compani
infecti
diseas
biotechnolog
could
endur
risk
mani
might
instead
simpli
continu
manufactur
dose
earlier
gener
respigam
synagi
rather
boldli
attempt
bring
forward
new
product
seemingli
increment
improv
summari
recent
develop
broaden
util
pathogen
rang
mab
therapeut
multidrug
resist
expect
futur
effici
mab
product
method
combin
ration
use
proven
polyclon
ig
method
enabl
us
predict
ab
therapi
infecti
pathogen
continu
lead
treatment
emerg
difficult
contain
infecti
diseas
